Sciclone -- Biotech-Perle mit schwarzen Zahlen - 500 Beiträge pro Seite

[CaptainChaos]

Sciclone ist neben Avant mein Biotech Favorit des nächsten Jahres:

86 % Umsatzerhöhung
Breakeven bereits erreicht
Top-Firma des Silicon Valley (Awards)
Zadaxin in der Bekämpfung der Hepatitis B + C anerkannt.
Vermarktung des Medikaments in 18 Staaten der Welt, darunter auch Kanada und Italien.

Wie sind die Meinungen zu Sciclone ?

[CaptainChaos]

Neben AVAN, CRIS, CYTO und KOOL ist Sciclone langfristig in meinem Depot. Bei den letzten Quartalszahlen hat SCLN das Breakeven erreicht und wird aller Vorausssicht nach im nächsten Quartal schwarze Zahlen schreiben ( Zadaxin). Derzeitiges Kursniveau wie MEDX im November 1999.


SciClone Pharmaceuticals Named One of the 500 Fastest Growing Technology Companies in North America

PR Newswire
November 16, 2000 9:20am
SAN MATEO, Calif., Nov 16, 2000 /PRNewswire via COMTEX/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the Company has been recognized as part of the Deloitte & Touche "Technology Fast 500" award in year 2000 for the 500 fastest growing technology companies in the U.S. and Canada. Rankings are based on five-year percentage revenue growth from 1995 to 1999. SciClone`s revenue increase of 3,342 percent over the period gave the company a ranking of 123 on the list of 500 companies.

Only 9 percent of the "Technology Fast 500" companies for year 2000 are in the biotechnology industry. More than 60 percent of the companies achieving rankings are in software or internet-related industries. SciClone previously was announced as a member of the Deloitte & Touche "Fast 50" for Silicon Valley technology companies, based on the same criteria.

"Few biopharmaceutical companies had product revenues in 1995 and even fewer have achieved the revenue growth necessary to break even on an operating cost basis," said Donald R. Sellers, SciClone`s President and Chief Executive Officer. "I`d like to congratulate every SciClone employee for their contributions in achieving this prestigious ranking. We look forward to the next five-year period as the opportunity not only to continue this growth, but to begin to realize the full potential of our company."

"The vision, drive and determination of the leaders and employees at SciClone propelled their company to an elite status as one of the 500 fastest-growing technology firms in the U.S. and Canada," said Mark A. Evans, managing director of Deloitte & Touche`s Technology & Communications Group. "We applaud their dedication to excellence while maintaining a fast-paced growth, and commend them for making the Deloitte & Touche Technology Fast 500."

SciClone Pharmaceuticals is a global specialty biopharmaceutical company that acquires, develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. The Company is targeting cancer, hepatitis B, hepatitis C and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at WWW.SCICLONE.COM or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market under the symbol SCLN.

Deloitte & Touche, one of the nation`s leading professional services firms, provides assurance and advisory, tax and management consulting services through 30,000 people in more than 100 U.S. cities. Deloitte & Touche is part of Deloitte Touche Tohmatsu, a global leader in professional services with more than 90,000 people in over 130 countries. Deloitte & Touche refers to Deloitte & Touche LLP, Deloitte Consulting LLC and related entities. For additional information, please visit Deloitte & Touch`s website at WWW.US.DELOITTE.COM.

SOURCE SciClone Pharmaceuticals



CONTACT: investors, Ruth Koh of SciClone Pharmaceuticals, 650-358-3437;
or media, Ana Kapor of Noonan Russo Communications, Inc., 415-677-4455, for
SciClone Pharmaceuticals

URL: HTTP://WWW.US.DELOITTE.COM
HTTP://WWW.SCICLONE.COM
HTTP://WWW.PRNEWSWIRE.COM

(C) 2000 PR Newswire. All rights reserved.
KEYWORD: California INDUSTRY KEYWORD: MTC BIO SUBJECT CODE: OTC



Source: PR Newswire

[CaptainChaos]

Ich habe mir heute die HP von Sciclone näher angesehen. Die Homepage ist sehr ansprechend. Ich verstehe eigentlich nicht, dass bei den Neuigkeiten des Jahres 2000 dieser Wert so niedergeprügelt wurde, während Biotechfirmen, die weit von den schwarzen Zahlen entfernt sind in den Himmel gehoben wurden und ihre dreisteligen Kurse vorwiegend mit der zukünftigen Phantasie begründen.

Ich bin von SCLN überzeugt und bleibe investiert. Sollte mein Cash - Bestand sich (hoffentlich) verbessern, werde ich nachordern. Nachfolgend die News 2000, die m.E. überzeugend sind:


To read the full text of any News Release, simply click on the date.

November 2000

November-16-2000
SciClone Pharmaceuticals Named One of the 500 Fastest Growing Technology Companies in North America

November-10-2000
SciClone Pharmaceuticals Announces successful Reformulation of CPX for Expanded Phase 2 Studies in Cystic Fibrosis Patients
-- Cystic Fibrosis Foundation Pledges Up To An Additional $1 Million In CPX Clinical Development Funding Pending Phase 2 Results --

November-3-2000
SciClone Pharmaceuticals Receives 2000 "New Product / Technology Development" Award From City of San Mateo in Silicon Valley, CA

October 2000

October-31-2000
New Study Helps Explain the Fundamental Role of SciClone`s ZADAXIN® in the Successful Treatment of Chronic Hepatitis B
-- Data Presented at the 51st Annual Meeting of the American Association for the Study of Liver Diseases --

October-26-2000
SciClone Pharmaceuticals Completes North American Patent Position for ZADAXIN® in Hepatitis C

October-19-2000
SciClone Pharmaceuticals Reports Third Quarter Results
- Revenues Increase 86% -
- Achieves First Breakeven Quarter -

September 2000

September-28-2000
SciClone Strengthens Latin American Position for ZADAXIN in Hepatitis C

September-22-2000
SciClone Pharmaceuticals Named One of Silicon Valley`s 50 Fastest Growing Technology Companies

August 2000

August-21-2000
SciClone Pharmaceuticals Expands Board of Directors

August-7-2000
SciClone`s ZADAXIN® Receives Expanded Approval in Argentina for Hepatitis B and Hepatitis C

August-2-2000
SciClone Pharmaceuticals Launches ZADAXIN® in Mexico

July 2000

July-31-2000
SciClone`s ZADAXIN® Prevents Formation of Lung Tumors in NIH Study

July-17-2000
SciClone Pharmaceuticals Announces Record Revenues for the Second Quarter of 2000
-10th Consecutive Quarter of Double-Digit Revenue Growth-

June 2000

June-6-2000
SciClone Pharmaceuticals Granted U.S. Patent for the Use of ZADAXIN® to Treat Heptatitis B
-SciClone Strengthens U.S. Patent Coverage Around its Lead Immunotherapy-

May 2000

May-23-2000
SciClone`s ZADAXIN® Commercially Available in Italy

May-22-2000
New Study Shows Improvement in Quality of Life for Chemotherapy Patients Receiving SciClone`s ZADAXIN®

May-17-2000
SciClone Pharmaceuticals Granted U.S. Patent for DAX, a Promising Cystic Fibrosis Drug Candidate
- SciClone Consolidates Its Patent Position Around Novel Drugs for Cystic Fibrosis -

April 2000

April-27-2000
SciClone`s First Quarter ZADAXIN® Sales Increase 122%

April-13-2000
SciClone`s ZADAXIN® Approved in South Korea

April-6-2000
ZADAXIN Plus Chemotherapy Shows Promise for Improved Survival in Advanced Skin Cancer
-- Phase 2 Results Published In Melanoma Research --

March 2000

March-22-2000
FDA Grants Orphan Drug Status to Sciclone`s ZADAXIN® for the Treatment of Liver Cancer

March-17-2000
SciClone Receives Three New ZADAXIN® Marketing Approvals

March-13-2000
SciClone and Sigma-Tau Sign Expanded ZADAXIN Hepatitis C and Cancer Partnership for Europe
Two Pivotal Phase 3 Hepatitis C Trials Planned For This Year


March-1-2000
New Study Shows ZADAXIN`s Dual Role in Immune Recognition of and Response to Cancer and Infection
-- Mechanism Of Action Study Published In European Journal Of Immunology --


February 2000

February-23-2000
SciClone Awarded $300,000 Grant to Study New Immunomodulator for Tuberculosis

February-15-2000
SciClone Pharmaceuticals Moves Forward with Development of CPX for Cystic Fibrosis

February-3-2000
SciClone Pharmaceuticals Reports 1999 Results
- 152% Gain in 1999 Revenue -

January 2000

January-27-2000
SciClone Initiates U.S. Phase 2 Study of ZADAXIN Plus Lamivudine for Hepatitis B

January-19-2000
SciClone Pharmaceuticals Expands Capital Base

[CaptainChaos]

Wieder eine gute Nachricht. In Australien laufen Tests bezüglich der Wirksamkeit von Zadaxin bei der Behandlung von Hautkrebs. Sciclone ist optimistisch, dass die Testreihe zu guten Ergebnissen führen wird.

Australien hat ja ein großes Problem hinsichtlich des Ozonlochs und der damit einhergehenden UV-Strahlung sowie dem hohen Hautkrebsrisiko.

SciClone Pharmaceuticals Initiates ZADAXIN(R) Malignant Melanoma Clinical Study in AustraliaPure Immunotherapy Approach; No Chemotherapy in Protocol
SCLN


RELATED QUOTES

SCLN 6.41 1/16
RELATED TOPICS
cnw
annual report
australia
cancer
cellular
clinical
corporate
district of columbia


SAN MATEO, Calif., Nov 20, 2000 (Canada NewsWire via COMTEX) -- SciClone Pharmaceuticals (Nasdaq: SCLN ) announced that a new ZADAXIN(R) clinical study for malignant melanoma, the deadliest form of skin cancer and one of the most rapidly increasing types of cancer worldwide, has been initiated in Australia.

This study, coordinated by Dr. Peter Hersey of the Royal Newcastle Hospital in New South Wales, one of Australia`s leading melanoma experts and an acknowledged world leader in melanoma treatment research, will be based on immunotherapy treatment. The study is designed to show whether ZADAXIN can enhance immunity, elevate T-cell counts and contribute, in combination with active immunization, to a specific melanoma immune response.

Advanced-stage, metastatic melanoma patients with low cell-mediated immunity, which is thought to be responsible for the aggressive nature of this type of cancer, will be administered an induction course of ZADAXIN to improve their overall cellular immune responses. Subsequently, half of the patients will be administered vaccinations with mature dendritic cells (DC), the most powerful antigen presenting cell, which have been infused with melanoma antigen. The other half of the patients will receive the DC vaccinations plus ZADAXIN, which has been shown to significantly increase the levels of CD4 and CD8 T-cells. This combined immunotherapy approach is expected to allow physicians to induce responses in otherwise resistant melanomas without adding the adverse effects of cancer chemotherapy.

"Melanoma is largely unresponsive to available chemotherapy or biologic agents, and we therefore have a great interest in novel immunotherapeutic approaches," said Dr. Hersey. "DC-based immunization shows great early promise, and ZADAXIN may prove to be a powerful adjuvant for combination immunotherapy."

"Oncology is clearly the next frontier for ZADAXIN and we are seeing an increasing number of investigators including ZADAXIN in their cancer trials," said Donald R. Sellers, SciClone`s President and Chief Executive Officer. "It is exciting to be working with Dr. Hersey, who has taken the lead in confronting the significant melanoma problem in Australia. Malignant melanoma also will be one of the primary goals of our U.S. clinical program for ZADAXIN in cancer."

Sellers noted that in previously published studies, ZADAXIN increased the effectiveness of chemotherapy in malignant melanoma patients (50% response rate in combination with dacarbazine and interferon). ZADAXIN also had a significant impact on tumor progression in mice implanted with melanoma cancer cells (23% tumor-free one year after treatment with combination therapy).

No proven life-prolonging therapy yet exists for metastatic malignant melanoma, the leading cause of skin cancer death. Melanoma is one of the most prevalent cancers in Australia. According to the Anti-Cancer Council of Victoria in Australia, Australians suffer the highest rates of skin cancer in the world. Two out of three Australians develop some form of skin cancer during their lives. Skin cancer costs the Australian public health system more than AUS$300 million annually. In the U.S., approximately 47,000 new cases are diagnosed each year and 7,700 deaths are reported.

ZADAXIN, a synthetic peptide that enhances the immune system, has been administered to over 3,000 subjects in over 70 clinical trials covering a broad range of diseases, and an estimated 7,000 patients commercially, with virtually no serious drug related adverse effects or toxicities. ZADAXIN is approved for sale in 20 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. In the U.S., where SciClone retains all ZADAXIN rights, a pivotal phase 3 ZADAXIN hepatitis C program and a phase 2 ZADAXIN cancer program is scheduled to start by the end of the year. ZADAXIN is currently in a phase 2 program in the U.S. in combination with lamivudine for the treatment of hepatitis B. In Europe, where SciClone has exclusively partnered with Sigma-Tau S.p.A., a pivotal phase 3 ZADAXIN hepatitis C program is scheduled to start by year-end and will complement the Company`s U.S. hepatitis C program. In Japan, where SciClone has exclusively partnered with Schering-Plough, K.K., ZADAXIN is in a pivotal phase 3 program for hepatitis B and a phase 2 program for hepatitis C.

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. The Company is currently targeting malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market(R) under the symbol SCLN.

The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events, including the ongoing and prospective development and commercialization of ZADAXIN immunotherapy for cancer, including metastatic malignant melanoma and the timing of the start and potential for success of the Company`s U.S. phase 2 studies for metastatic malignant melanoma in the U.S. and Australia. Due to the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company`s filings with the Securities and Exchange Commission, particularly its Annual Report on Form 10-K for the year ended December 31, 1999.


CONTACT: For further information: Ruth Koh, Investor Relations of SciClone
Pharmaceuticals, 650-358-3437; or Ana Kapor of Noonan Russo Communications,
415-677-4455, for SciClone Pharmaceuticals

URL: Web site: http://www.sciclone.com
News release via Canada NewsWire, Toronto 416-863-9350 -ME-

Copyright (C) 2000 CNW, All rights reserved

-0-


KEYWORD: SAN MATEO, Calif.
INDUSTRY KEYWORD: MTC
SUBJECT CODE: PDT

[CaptainChaos]

Sciclone wurde gestern aufgrund einer Gewinnwarnung für das 4. Quartal mit einem Kursabschlag von - 37 % abgestraft. Das tut weh, ändert jedoch nichts an meiner positiven Einschätzung. Stay long.


SciClone Comments on Product Revenue Expectations for Fourth QuarterAnticipated Q4 Sales Result May Not Affect Earnings Expectations or Cashflow
SCLN



SAN MATEO, Calif., Dec 4, 2000 /PRNewswire via COMTEX/ -- SciClone Pharmaceuticals (Nasdaq: SCLN ) today announced updated expectations for product revenues in the fourth quarter of 2000. The Company now expects that product sales for the fourth quarter of 2000 will fall below those of the year`s third quarter. For the year, the Company still expects significant sales growth over the previous year.

Donald Sellers, SciClone`s President and Chief Executive Officer said, "It is still too early in the quarter to state what the range of product sales will be, however we are certain it will be below the level of last quarter. Although in-the-market consumption of ZADAXIN(R) continues to increase around the world, it has not kept up with the expectations of certain importers. However, at this time we believe we may still have a breakeven or profitable quarter from operations. We also believe the slow down this quarter will not impact our 2001 sales and operational results."

The Company indicated that its principal financial goal from current international ZADAXIN sales is to maintain a neutral or better cash position as the Company engages in late-stage ZADAXIN trials in the U.S., Europe and Japan.

SciClone Pharmaceuticals is a global specialty biopharmaceutical company that acquires, develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. The Company is targeting cancer, hepatitis B, hepatitis C and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market under the symbol SCLN.

The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events, including expected product sales and the ongoing and prospective development and commercialization of ZADAXIN immunotherapy in the U.S., Europe and Japan. Actual results may vary based on a number of factors including actual sales during the month of December and in subsequent quarters, the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company`s filings with the Securities and Exchange Commission, particularly the Company`s Annual Report on Form 10-K for the year ended December 31, 1999.

SOURCE SciClone Pharmaceuticals


CONTACT: investors, Ruth Koh of SciClone Pharmaceuticals, 650-358-3437
/Company News On-Call: http://www.prnewswire.com/comp/775865.html" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/775865.html or fax,
800-758-5804, ext. 775865

URL: http://www.sciclone.com
http://www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.

-0-


KEYWORD: California
INDUSTRY KEYWORD: MTC
SUBJECT CODE: ERP

[CaptainChaos]

Hier nochmal eine Zusammenfassung aus Börse.Go

Die Meldung rechtfertigt m.E. nicht den Kursabschlag von mehr als 36 %. Ich hoffe, dass die nachfolgend angesprochenen Testreihen positiv verlaufen. Derzeit ergibt sich daraus eine günstige Einstiegsposition.

05.12. 07:12
SciClone - Umsatzrückgang
--------------------------------------------------------------------------------


SciClone Pharmaceuticals fiel im gestrigen Handelsverlauf um über 36%, nachdem ein Umsatzrückgang auf sequentieller Basis bekannt wurde. Im dritten Quartal wurden Umsätze in Höhe von $4,7 Mio. erwirtschaftet, ein Profitables viertes Quartal sei jedoch immer noch möglich. Priorität habe nun die Bewahrung der Cash-Position, da man mit dem Hepatitis-Medikament in Japan, den USA und Europa letzte klinische Tests durchführe. Zum 30 September verfügte man über $17,5 Mio. Barmittel.

Biotechnologie-Aktien gehörten am Montag zu den grrößten Verlierern. Der AMEX Biotechnologie Index verlor 4,2%, der Nasdaq Biotechnologie Index gab 3,7% ab.

© BörseGo.de

[CaptainChaos]

Ich fühle mich niedergemetzelt.

[SidBn]

@ captain

Kopf hoch,stay long !

Sid

[Togotom]

Ich sage nur, nichts wie rein in den Wert. Super Management, super Produktreihe und finanzielle Sicherheit. Kaufen soll man bei Tiefstständen. Deswegen werden die jetzigen Käufer zu den Gewinnern der nächsten zwei Jahre gehören.

[CaptainChaos]

Danke für die aufmunternden Worte an SidBn und Togotom.
Ihr habt selbstverständlich beide vollkommen recht.
Wenn die letzten klinischen Testreihen in Japan, Eurtopa und den USA gelingen sollten, ksnn es ganz schnell wieder Richtung Norden gehen.

Gruss


CC

[CaptainChaos]

Aufmunternde Nachrichten:

SciClone empfängt europäisches Patent für die Behandlung von Hepatitis C mit ZADAXIN(r) - Firma verstärkt Patentansprühe für seine Immuntherapie - SCLN
http://investorstockpoint.com/quote.asp?Mode=CHART&Symbol=SC…



SAN MATEO, Calif., Dec 06, 2000 (Canada NewsWire via COMTEX) -- SciClone Pharmaceuticals (Nasdaq: SCLN ) today announced that the European Patent Office has allowed the Company a patent covering the use of ZADAXIN(R) for the treatment of hepatitis C in non-responders. A non-responder is a hepatitis C patient that has been treated for one year with current therapy and at the end of therapy has not cleared the virus. ZADAXIN, SciClone`s lead drug, is a synthetic immunomodulator with wide ranging applications in the treatment of several life threatening diseases including hepatitis C, hepatitis B and cancer.
"Hepatitis C is an enormous health burden to the world," commented Alfred Rudolph, M.D., SciClone`s Chief Operating Officer. "We are excited by the prospect of developing ZADAXIN for this unmet medical need."
According to the World Health Organization, (WHO), hepatitis C affects approximately 170 million people, or 3% of the total world`s population. Of these, an estimated 8.9 million are in Europe. These numbers are considered to be an underestimate due to the high number of affected individuals who are unaware of their infection.
"ZADAXIN is an immmodulator that continues to demonstrate significant clinical benefits for patients suffering from serious diseases such as chronic hepatitis and various cancers," said Donald R. Sellers, SciClone`s President and Chief Executive Officer. "This patent further strengthens our intellectual property position for the commercial use of ZADAXIN."
ZADAXIN, a synthetic peptide that enhances the immune system, has been administered to over 3,000 subjects in over 70 clinical trials covering a broad range of diseases, and an estimated 7,000 patients commercially, with virtually no serious drug related side effects or toxicities. ZADAXIN is approved for sale in 20 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. ZADAXIN is currently in a phase 2 program in the U.S. in combination with lamivudine for the treatment of hepatitis B. In Europe, where SciClone has exclusively partnered with Sigma-Tau S.p.A., a pivotal phase 3 ZADAXIN hepatitis C program will complement the Company`s U.S. hepatitis C program which is scheduled to start by year-end. In Japan, where SciClone has exclusively partnered with Schering-Plough, K.K., ZADAXIN is in a pivotal phase 3 program for hepatitis B and a phase 2 program for hepatitis C.
SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. The Company is currently targeting malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800/724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market(R) under the symbol SCLN.
The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events, prospective development and commercialization of ZADAXIN immunotherapy in the U.S., Europe and Japan for cancer, hepatitis B and hepatitis C, the timing of the start and potential for success of the Company`s U.S. phase 2 programs for cancer and its ZADAXIN phase 3 program for hepatitis C in the U.S., and Sigma-Tau`s ZADAXIN phase 3 program for hepatitis C in Europe. Due to market factors and the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company`s filings with the Securities and Exchange Commission, particularly the Company`s Annual Report on Form 10-K for the year ended December 31, 1999.
CONTACT: For further information: Ruth Koh, Investor Relations of SciClone
Pharmaceuticals, 650- 358-3437; or Ana Kapor of Noonan Russo Communications,
Inc., 415-677-4455, for SciClone Pharmaceuticals

URL: Web site: http://www.sciclone.com
News release via Canada NewsWire, Toronto 416-863-9350 -ME-

Copyright (C) 2000 CNW, All rights reserved

-0-

[CaptainChaos]

SciClone erhält Patent


SciClone Pharmaceuticals gab heute bekannt, dass das europäische Patentamt, dem Unternehmen ein Patent erteilt hat, das das Medikament ZADAXIN® für die Hepatitis C-Behandlung betrifft.

ZADAXIN ist SciClones wichtigstes Mittel und ein synthetischer Immunmodulator zur Behandlung von Hepatitis C, -B und Krebs.

"Hepatitis C ist eine enorme Gefahr für die Gesundheit der Menschheit" meinte Alfred Rudolph, SciClones Chief Operating Officer. " Wir sind sehr engagiert und erfreut, dass ZADAXIN gegen diese Krankheit vorgehen kann."




Quelle: Finance Online 06.12.2000 19:50

[CaptainChaos]

Hallo SCLN - Freunde,

gestern zog SCLN bei starken Umsätzen um +28 % nach NORDEN: Ich hoffe, dass die Amerikaner die gute Nachricht vom Mittwoch veranlaßt hat, wieder in SCLN einzusteigen.

Übrigens halte ich für mutig von SCLN in die Behandlung von Non-responders einzusteigen. Das sind nach meinem Erkenntnisstand Hepatitis - Patienten, bei denen über einen Zeiraum von einem Jahr eine anderweitige Medikamentation erfolglos blieb. Sollte Zadaxin bei diesen Patienten anschlagen ist das aus meiner SIch ein Durchbruch für Zadaxin. Das weltweite Interesse ist jedenfalls groß. In 20 Staaten weltweit erfolgt bereits der Vertrieb. In 70 Kliniken weltweit laufen Versuchsreihen mit Zadaxin.

Für mich steht fest, dass Sciclone von seinem Produkt überzeugt ist und sich deshalb auch an Non-Responders heranwagt.

Gruss

[CaptainChaos]

Ich bleibe von Sciclone überzeugt.
Ich ärgere mich nur, dass ich vor drei Monaten eingestiegen bin.

[CaptainChaos]

Sciclone - News -- ein neuer Investor:

SciClone Pharmaceuticals Completes $4.9 Million Financing
SCLN


RELATED QUOTES

SCLN 3.47 -0.34
UBS 155.28 -0.17
RELATED TOPICS
cnw
cancer
corporate
executive
hiv
investment
pharmaceutical
pharmaceuticals


SAN MATEO, Calif., Dec 19, 2000 (Canada NewsWire via COMTEX) -- SciClone Pharmaceuticals, Inc., (Nasdaq: SCLN ) today announced the purchase by an investment affiliate of UBS AG, one of the world`s five largest financial institutions, of a $4 million senior unsecured convertible note. SciClone also received $900,000 for the right to purchase an additional $5.9 million of convertible notes.

The new $4 million note is convertible into 407,610 shares of SciClone common stock at a fixed conversion price of $9.8133 per share. The note will accrue interest at a rate of 6% per year and will mature in December 2005. The note is not convertible prior to December 2001.

In addition, SciClone received $900,000 for granting the investor the right to purchase approximately $5.9 million of senior unsecured convertible notes due December 2005. If issued, the notes will bear no interest (zero coupon) and will be convertible into 407,610 shares of SciClone common stock at a fixed conversion price of $14.5066 per share.

"We are grateful that this prestigious institutional investor shares our confidence in SciClone`s future," said Donald R. Sellers, SciClone`s President and Chief Executive Officer. "The strategic benefits of the arrangement dictated the addition of the funds to our balance sheet at this time."

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. The Company is currently targeting malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals, are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market(R) under the symbol SCLN.


CONTACT: For further information: investors, Ruth Koh of SciClone
Pharmaceuticals, 650-358-3437; or media, Ian McConnell of Noonan Russo
Communications, Inc., 415-677-4455, for SciClone Pharmaceuticals

URL: Web site: http://www.sciclone.com
News release via Canada NewsWire, Toronto 416-863-9350 -ME-

Copyright (C) 2000 CNW, All rights reserved

-0-


KEYWORD: SAN MATEO, Calif.
INDUSTRY KEYWORD: MTC
SUBJECT CODE: FNC

[CaptainChaos]

Allen Sciclone - Fans ein frohes neues Jahr und steigende Kurse in 2001.

Ich bin mir sicher, dass SCLN in 2001 schwarze Zahlen schreiben wird und die heutigen Kurse bald der Vergangenheit angehören.

[CaptainChaos]

Und wieder gute Nachrichten:

SciClone Named One of 10 Best Health Care Websites

PR Newswire
January 2, 2001 9:30am
SAN MATEO, Calif., Jan 2, 2001 /PRNewswire via COMTEX/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) said its website - WWW.SCICLONE.COM - has been named one of the 10 best sites in the health care industry by Med Ad News, a leading trade publication for healthcare marketing and advertising professionals. SciClone was chosen as one of the 10 best following the publication`s review of more than 1,500 healthcare websites.

The top 10 sites were chosen for superior functionality, design, content, originality and effectiveness. The 10 award winning sites represent two pharmaceutical brands, five biotechnology companies (including SciClone) and three drug discovery companies.

"The Internet is an important tool for a growing company with a marketed product in diverse geographic markets because it is truly international," said Donald R. Sellers, SciClone`s President and Chief Executive Officer. "Our user feedback has consistently been very positive and now it is gratifying to be acknowledged by professional reviewers as well. The excellence of the SciClone.com website is indicative of the energy and commitment we make to all facets of our business."

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. The Company is currently targeting malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV, drug- resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at WWW.SCICLONE.COM or by calling the Company`s Investor Relations Department at 800/724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market(R) under the symbol SCLN.

SOURCE SciClone Pharmaceuticals



CONTACT: Ruth Koh, Investor Relations of SciClone Pharmaceuticals,
650-358-3437, or Ana Kapor of Noonan Russo Communications, Inc., 415-677-4455,
for SciClone Pharmaceuticals
/Company News On-Call: HTTP://WWW.PRNEWSWIRE.COM/COMP/775865.HTML or fax,
800-758-5804, ext. 775865

URL: HTTP://WWW.SCICLONE.COM
HTTP://WWW.PRNEWSWIRE.COM

(C) 2001 PR Newswire. All rights reserved.
KEYWORD: California INDUSTRY KEYWORD: MTC PUB MLM



Source: PR Newswire

[Albatossa]

Hallo CaptainChaos,

auch immernoch bei Sciclone dabei?

Eigentlich hat sich bei Sciclone nichts verschlechtert! Ich werde ganzgemütlich mein Depot mit Sciclone weiter aufstocken. Eigentlich ist doch jetzt die schönste Zeit sich billig in gute und nachhaltige Aktien wie Sciclone einzukaufen.

Gruß Albatossa

[CaptainChaos]

Hallo Albatossa

schön, dass Du auch noch dabei bist. Ich stocke derzeit SCLN und CYTO auf. Bei den Preisen kann nicht viel runtergehen. Beide Firmen haben m.E. viel Potential nach oben. Vertex, Millenium oder Medarex sind sicherlich hervorragende Firmen, haben aber derzeit zuviel Potential nach unten.


Gruss


CC

[CaptainChaos]

Nachfolgende Diskussion hält sich hartnäckig in den US-Boards. Wenn das so kommen sollte, sehen wir m.E. schnell wieder zweistellige Kurse:

Aus Clearstation.com:

Title : Could this be the week??

Could this week be the week that SCLN announces their partnership with Schering Plough or Roche Labs for phaseiii U.S.A. clinical trials of Zadaxin? I think the month of january and february will bring some very good news about Zadaxin and CPX.

P.S. Eine Kooperation mit Schering oder Roche ist keine Tatsachenbehauptung, sondern ein sich hartnäckig haltendes Gerücht in den US - Boards.

Gruss

[CaptainChaos]

Die Story geht weiter:


SAN MATEO, Calif., Jan. 8 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the initiation of a U.S. Phase 2 study in patients with hepatocellular carcinoma, evaluating the effectiveness of
ZADAXIN(R), the Company`s immune system enhancer, in combination with radio frequency ablation (RFA). RFA is a procedure which destroys tumors by radio
waves delivered via a probe-bearing needle, and is increasingly used to treat primary liver cancer as an alternative to surgical resection or localized
chemotherapy. The trial`s lead investigator is Adrian Di Bisceglie, M.D., Associate Chairman of Medicine, Saint Louis University and Medical Director of the American Liver Foundation.
The goal of the open label, randomized, controlled study is to evaluate whether a ZADAXIN-enhanced immune response may contribute to the effectiveness of tumor therapy with RFA. Patients will be randomized to each of two treatment arms: RFA alone or RFA plus ZADAXIN. ZADAXIN will be given for
6 months, and all patients will have an additional 12 months of follow-up.
Primary efficacy endpoints will be tumor response and survival. Tumor response will be measured by assessing the number of patients with undetectable tumors and those with metastases or new tumors. A secondary endpoint will be the number of patients who become eligible for liver transplantation due to a reduction of tumor burden.
"Liver cancer is one obvious target for ZADAXIN`s clinical development in oncology, especially because of its association with chronic hepatitis B and chronic hepatitis C. This U.S. study is part of the beginning of an
aggressive and broad-based U.S. oncology program," said Alfred R. Rudolph, MD, SciClone`s Chief Operating Officer. "We have seen early indications of ZADAXIN`s effect in combination therapies for other types of cancer such as malignant melanoma, where trials have recently begun in Australia." Hepatocellular carcinoma (HCC) accounts for more than 80 percent of all primary liver tumors and is the most prevalent malignancy in the world, linked closely to chronic hepatitis B or chronic hepatitis C infection. In the U.S., there are some 4,000 to 6,000 cases of HCC diagnosed each year. The worldwide annual incidence is approximately 1 million new cases. With early
identification, HCC is treated with reasonable success by surgery or liver transplantation. However, in later stages, prognosis is poor. Systemic chemotherapy has produced disappointing results. Localized chemotherapy such
as transarterial chemoembolization (TACE) has achieved higher response rates, but is not always feasible for technical or clinical reasons. In a previous pilot human study, patients treated with the combination of ZADAXIN plus TACE showed longer survival than the control group treated with TACE alone, reaching statistical significance at 7 months after the end of treatment.
More recently, newer tumor-ablation procedures such as RFA have become more commonly used in clinical practice for HCC.
ZADAXIN, a synthetic peptide that enhances the immune response, has been administered to over 3,000 subjects in over 70 clinical trials covering a broad range of diseases, and an estimated 7,000 patients commercially, with
virtually no serious drug related side effects or toxicities. ZADAXIN is approved for sale in 20 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. ZADAXIN is currently in a phase 2 program in the U.S. in combination with lamivudine for the treatment of hepatitis B. In Europe, where SciClone
has exclusively partnered with Sigma-Tau S.p.A., a pivotal phase 3 ZADAXIN hepatitis C program will complement the Company`s U.S. hepatitis C program. In Japan, where SciClone has exclusively partnered with Schering-Plough, K.K., ZADAXIN is in a pivotal phase 3 program for hepatitis B and a phase 2 program for hepatitis C.

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for the treatment of a broad range
of the world`s most serious diseases. The Company is currently targeting malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate
information from SciClone Pharmaceuticals are available on the Internet at http://www.sciclone.com or by calling the Company`s Investor Relations Department at
800/724-2566. SciClone`s Common Stock is listed on The Nasdaq National
Market(R) under the symbol SCLN.

The information in this press release includes certain forward-looking
statements concerning the Company`s current expectations regarding future
events, including statements regarding ongoing and prospective development and
commercialization of ZADAXIN as a potential immunotherapy for cancer,
including HCC in the U.S., timing of commencement and expected completion of
the HCC phase 2 trial and the efficiency and expense of such trial. These
forward-looking statements are subject to risks and uncertainties that may
cause actual results to differ from those stated in this release. These risks
and uncertainties include the speed with which patients are enrolled in the
programs, unexpected adverse results to patients during the trials, and other
unexpected delays or other events that could prolong the studies or result in
unanticipated expense. Additional risks and uncertainties include those
reflected in the Company`s filings with the Securities and Exchange
Commission, particularly the Company`s Annual Report on Form 10-K for the year
ended December 31, 1999.




SOURCE SciClone Pharmaceuticals

[Babyelch]

Wollte nur kurz mitteilen, daß ich seit heute mit SCLN wieder im Plus bin. Nachdem ich bei 10 Euro die erste Position gekauft habe, bei 8 und 3,7 Euro verbilligt habe ist der Kurs heute über meinen Durchschnittswert gestiegen. Weiter so.
Nochwas. Mir gefällt Sciclone sehr gut und ausgehend vom Tief bei 3,5 habe ich nichts dagegen, wenn sich der Kurs in den nächsten 3-5 Jahren weiter so schön entwickelt.

[Stockdreamer]

Es ist einfach wunderschön festzustellen, wie eine Aktie sich still und heimlich zu einem Renner entwickelt und praktisch täglich Kursgewinne ausweist, insbesondere wenn man zu einem günstigen Kurs, z.B. 4,90 eingestiegen ist. Auf der anderen Seite kann man kaum verstehen, warum noch nicht die große Masse der Anleger auf solche Biotechperlen wie Sciclone aufmerksam geworden ist, wie man aufgrund der wenigen Postings zu diesem Wert vermuten kann. Ich wünsche allen Mitaktionären noch viel Freude in der Zukunft an steigenden Kursen und der US-Firma noch zahlreiche Erfolgsmeldungen über die hervorragenden Produkte.

[CaptainChaos]

@ Stockdreamer,

lass uns die Kurse einfach nur geniessen bevor Daytrader und Shorties alles wieder dahin machen.

Darum ist es so ruhig hier.

Wenn die Zadaxin - Ergebnisse vorliegen, können wir immer noch lauter werden.

[DolleMARK]

Jetzt melde ich mich mal hier im Board. Weiss nicht, wie es Euch geht - aber ich fühle mich mit meinen Sciclones in den letzten Tagen sehr wohl. Jeden Tag zu beobachten, daß das Investment eine gute Idee war, das ist bei einem solchen Wert der zweiten Reihe schon eine beeindruckende Sache. Das man eigentlich keinen Analystenkommentar bekommen kann ist in diesen Tagen eigentlich ein sehr gutes Zeichen.
Aber etwas interessiert mich schon(Auch wenn es hier im Board noch relativ still ist):
1. Wie seht Ihr das langfristige Kursziel?
2. Kann mir jemand posten, wann die nächsten Zahlen und Ergebnisse veröffentlicht werden?
Ansonsten wünsche ich allen investierten Sciclonern viele solche steigenden Kurse. Oh, das habe ich mir ja selbst auch gewünscht.

Mit vielen Grüßen DolleMark

[CaptainChaos]

@DolleMARK,

die Q 4 - Zahlen sollen laut Stockpoint.com am 08.02.2001 kommen.

Hinsichtlich eines Kurszieles kann man keine Aussagen machen, da Zadaxin zwar schon Einnahmen einfährt, der große Durchbruch bislang aber noch ausblieb. Sollte sich Zadaxin, welches derzeit in 70 unterschiedlichen Testreihen erprobt wird ( Hepatitis B + C, Unterstützung Krebstherapien) in der Phase 3 erfolgreich sein, wird eine Menge Fantasie in SCLN liegen. Ich kann mich nicht festlegen, bin aber absolut positiv eingestellt, da weltweit in 20 Staaten eine Zulassung bereits erfolgt ist.

Gruss

CC

[CaptainChaos]

Sciclone - Zulassung in Indien !!!



SciClone``s ZADAXIN(R) Approved in India for Hepatitis B

SAN MATEO, Calif., Feb. 5 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that its lead drug, ZADAXIN(R), has been approved in India for the treatment of hepatitis B. SciClone reported that commercial introduction of ZADAXIN into the Indian market could begin as early as the second quarter of this year.

ZADAXIN, SciClone`s lead drug, is a synthetic preparation of thymosin alpha 1, a peptide that occurs naturally in humans and is an immune system enhancer ("ISE") that helps stimulate, maintain and direct the body`s antiviral or anticancer responses.

"The approval of ZADAXIN for the treatment of hepatitis B by the Indian Ministry of Health was based on the combined result of both Indian clinical data and the international clinical program that has already earned ZADAXIN marketing approvals in 20 other countries worldwide," said Donald R. Sellers, SciClone`s President and Chief Executive Officer. "As in China, our current lead market, this approval is for an imported finished form of ZADAXIN. Over the next few years we expect that India should become one of the more significant markets for ZADAXIN outside of the U.S., Europe and Japan. We are already working to expand this approval to include hepatitis C."

India, with a population of over one billion, is the second most populous country in the world. It is estimated that approximately 45 million people in India are infected by hepatitis B and approximately 10 million people are infected by hepatitis C. As in most of the world, many patients in India are not aware of the presence of the disease until liver cirrhosis has already occurred.

ZADAXIN has been administered to over 3,000 subjects in over 70 clinical trials covering a broad range of diseases and to an estimated 7,000 patients commercially with virtually no serious drug related adverse events or toxicities. ZADAXIN is approved for sale in 21 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. ZADAXIN is currently in a phase 3 program in the U.S. in combination with Pegasys(R) (pegylated interferon alfa-2a) for the treatment of hepatitis C, in a phase 2 program in combination with lamivudine for the treatment of hepatitis B and in a phase 2 trial for the treatment of liver cancer. In Europe, a pivotal phase 3 ZADAXIN hepatitis C program will complement the Company`s U.S. hepatitis C program. ZADAXIN is also in clinical trials in Japan and Australia.

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. The Company is currently targeting malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market(R) under the symbol SCLN.

The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events. This includes, the ongoing and prospective development and commercialization of ZADAXIN immunotherapy for hepatitis B, hepatitis C and cancer, the continued growth in ZADAXIN sales in India and the timeline of ZADAXIN launch in India. Due to market factors and the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company`s filings with the Securities and Exchange Commission.


--------------------------------------------------------------------------------
Contact:
Ruth Koh, Investor Relations of SciClone Pharmaceuticals,
650-358-3437

[CaptainChaos]

Weiss jemand , wo die Quartalszahlen bleiben. Die Zahlen waren doch für den 08.02.2001 angekündigt worden. Auf der HP von SCLN ist keine Äusserung zu finden.

[CaptainChaos]

Zahlen sollen heute kommen!!

[Babyelch]

Brrrrrrrr!
Ich möcht sie mir gar nicht ansehen.
Da schlaf ich lieber noch ein paar Jahre.

Nicht ernst gemeint, nur habe ich in den letzten Monaten bei einigen sehr aussichtsreichen Firmen einige Wunder (leider oft negativ) erlebt.

[CaptainChaos]

Lasst die Zahlen auf Euch wirken. Sollte heute Sell on Good News einsetzen, werde ich nachlegen.

Thursday February 15, 2001 06:30 AM
Company Press Release

SOURCE:


SciClone Pharmaceuticals Reports 2000 Results

Pivotal U.S. Phase 3 Trials for Hepatitis C
2nd Consecutive Breakeven per Share Quarter

SAN MATEO, Calif., Feb. 15 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced results for the fourth quarter and year ended December 31, 2000.

For the year ended December 31, 2000, SciClone reported total revenues increased 63 to 15,357,000, based entirely on sales of ZADAXIN(R), the Company`s immune system enhancer drug ("ISE"), compared to 9,398,000 of revenue (including contract revenue) during the previous year. The net loss for the year ended December 31, 2000 decreased 69 to 1,717,000 (0.06 per share), compared to a net loss of 5,467,000 (0.26 per share) for 1999.

For the fourth quarter ended December 31, 2000 SciClone reported product revenue of 2,977,000, compared to product revenue of 2,999,000 reported for the fourth quarter of the previous year. The Company had a breakeven fourth quarter of 2000, with a net loss of 117,000 (0.00 per share), compared to a net loss of 535,000 (0.02 per share) during the previous year`s fourth quarter.

SciClone`s cash and investments totaled 22,497,000 on December 31, 2000.

The Company noted that its cash position as well as anticipated growth, in addition to growth achieved in 2000, is expected to support the recently announced expanded U.S. phase 3 ZADAXIN clinical program for hepatitis C. This program was moved to the first quarter of 2001 in order to have access, at no out-of-pocket cost, to Pegasys(R), a new pegylated form of interferon. The Company will also continue the expanded U.S. phase 2 ZADAXIN clinical programs for cancer and the U.S. CPX cystic fibrosis clinical program. The Company said that, as previously reported, the fourth quarter did not show ZADAXIN sales growth. The Company indicated that although its emphasis is shifting to U.S. clinical programs with associated higher operating expenses, a significant 30 to 40 year on year sales growth is expected for 2001.

"Our gross margin, our cash, no-cost access to pegylated interferon and our confidence in ZADAXIN enable us to increase the U.S. phase 3 hepatitis C program from the single 500 patient study planned last summer to two 500 patient complementary studies," said Donald R. Sellers, SciClone`s President and Chief Executive Officer. "Although the related increase in clinical trial expenses will obviate profitability this year, two confirmatory U.S. studies should represent a substantial benefit when presenting to the FDA. The incremental gain in our U.S. hepatitis C clinical program`s strength and value as well as the breadth of our cancer and cystic fibrosis clinical programs is well worth this investment in our future."

FOURTH QUARTER 2000 HIGHLIGHTS -- Initiated a state of the art phase 2 ZADAXIN clinical trial for the
treatment of malignant melanoma, the deadliest form of skin cancer and
one of the most rapidly increasing types of cancer worldwide;
-- Presented at the 51st Annual Meeting of the American Association for
the Study of Liver Diseases (AASLD) study data confirming ZADAXIN`s
ability to activate T-cells (disease fighting white blood cells) and
helping to explain the fundamental role ZADAXIN plays in the successful
treatment of hepatitis B;
-- European Patent Office allowed SciClone a patent for use of ZADAXIN for
the treatment of hepatitis C in non-responders to current standard of
care;
-- Canadian Patent Office granted SciClone a patent for use of ZADAXIN for
the treatment of hepatitis C;
-- Reformulated CPX for an expanded phase 2 study program for the
treatment of cystic fibrosis;
-- Completed $4.9 million financing with an investment affiliate of UBS
AG, one of the world`s five largest financial institutions;
-- Recognized as part of the 2000 Deloitte & Touche "Technology Fast 500"
award as one of the 500 fastest growing technology companies in the
U.S. and Canada. SciClone was ranked 123 on the list of 500 companies;
-- Received the 2000 "New Product/Technology Development" award from the
City of San Mateo in Silicon Valley, CA., in its annual Outstanding
Business Awards program;
-- SciClone presented at the UBS Warburg Global Life Sciences Conference,
the RedChip.com Life Sciences 2000 Conference, and the
InformedInvestors.com Virtual BioPharma Stocks Forum. ZADAXIN, a synthetic preparation of thymosin alpha 1, a peptide that

occurs naturally in humans and is an immune system enhancer ("ISE") that helps stimulate, maintain and direct the body`s antiviral or anticancer responses, has been administered to over 3,000 subjects in over 70 clinical trials covering a broad range of diseases and to an estimated 7,000 patients commercially with virtually no serious drug related adverse events or toxicities. In addition to the recently announced approval in India, ZADAXIN received new or expanded marketing approvals in six other countries during 2000. ZADAXIN is now approved for sale in 21 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. ZADAXIN is currently in a phase 3 program in the U.S. in combination with Pegasys(R) (pegylated interferon alfa-2a) for the treatment of hepatitis C, in a phase 2 program in combination with lamivudine for the treatment of hepatitis B and in a phase 2 trial for the treatment of liver cancer. In Europe, a pivotal phase 3 ZADAXIN hepatitis C program will complement the Company`s U.S. hepatitis C program. ZADAXIN is also in clinical trials in Japan and Australia.

"ISE" is an acronym for an immune system enhancer drug, such as ZADAXIN, that helps stimulate, maintain and direct the body`s antiviral or anticancer responses.

CPX is an orally available new protein-repair therapy for the treatment of cystic fibrosis. Cystic fibrosis occurs when a mutated gene produces an abnormal protein that cannot properly move through a lung epithelial cell. In laboratory studies, CPX successfully binds to the defective protein and improves the ability of the protein to move through the cell, a process called trafficking. In such studies, CPX also improves the working function of the defective protein so that it can successfully transport chloride ions from the surface of the epithelial cells. Cystic fibrosis is the most common fatal genetic disease among Caucasians, affecting approximately 70,000 children and young adults worldwide, including approximately 30,000 in the U.S. and 30,000 in Europe. Tragically, 50 of cystic fibrosis patients may die by age 31. The annual average cost of care of a cystic fibrosis patient is approximately 50,000 per patient, including hospitalizations, chest physical therapy and medications.

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. The Company is currently targeting malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market(R) under the symbol SCLN.

The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events including the Company`s expectations regarding trends in revenues, gross margins and expenses and statements using the words "expects," "believes," "anticipates" or similar words. This includes the ongoing and prospective development and commercialization of ZADAXIN immunotherapy, CPX therapy and the commercial success and continued growth in ZADAXIN sales in 2001 and beyond. Actual events could differ materially from those projected herein, due to risks and uncertainties including market factors, competitive product introductions, the nature of product development, the progress or failure of clinical trials and the regulatory approval process. Additional risks and uncertainties, include those reflected in the Company`s filings with the Securities and Exchange Commission.

SCICLONE PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Unaudited) (Unaudited)
Three Months Three Months Year Year
Ended Ended Ended Ended
Dec 31, 2000 Dec 31, 1999 Dec 31, 2000Dec 31, 1999 Product revenue $2,977,000 $2,999,000 $15,357,000 $9,091,000
Contract revenue 0 0 0 307,000 Total revenue 2,977,000 2,999,000 15,357,000 9,398,000
Cost of product 616,000 576,000 3,113,000 1,761,000 Gross margin 2,361,000 2,423,000 12,244,000 7,637,000 Operating expenses:
Research and
development 286,000 964,000 4,182,000 4,604,000 Marketing 2,172,000 1,605,000 8,328,000 5,911,000 General and
administrative 731,000 666,000 2,930,000 2,978,000 Total operating
expenses 3,189,000 3,235,000 15,440,000 13,493,000
Loss from operations (828,000) (812,000) (3,196,000) (5,856,000) Interest and
investment income,
net 711,000 277,000 1,479,000 389,000 Net loss (117,000) (535,000) (1,717,000) (5,467,000)
Basic net loss per
share ($0.00) ($0.02) ($0.06) ($0.26) Weighted average
shares used in
computing basic net
loss per share
amounts 31,936,173 25,034,273 29,904,924 21,162,936
SCICLONE PHARMACEUTICALS
CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS December 31, December 31,
2000 1999
(unaudited) Cash and cash equivalents/Short-term
investments $22,497,000 $3,621,000
Accounts receivable, net 8,621,000 4,343,000
Inventory 2,020,000 1,081,000
Other assets 3,029,000 4,079,000
Total assets $36,167,000 $13,124,000
LIABILITIES AND SHAREHOLDERS` EQUITY Total liabilities $8,090,000 $3,823,000
Total shareholders` equity 28,077,000 9,301,000
Total liabilities and shareholders`
equity $36,167,000 $13,124,000

SOURCE SciClone Pharmaceuticals, Inc.



--------------------------------------------------------------------------------
Contact:
Ruth Koh, Investor Relations of SciClone Pharmaceuticals, Inc.,
650-358-3437; or Ana Kapor of Noonan Russo Communications, Inc., 415-677-4455,
for SciClone Pharmaceuticals, Inc.

[CaptainChaos]

Die Erwartungen hinsichtlich des Umsatzwachstums bringen Fantasie in den Kurs:



SciClone trifft Erwartungen
Die SciClone Pharmaceuticals Inc. meldete am Mittwoch einen geringer als erwarteten Verlust für das vierte Quartal, welcher im Rahmen der Erwartungen lag.

Der Verlust lag demnach bei 117.000 Dollar oder null Cents je Aktie verglichen mit 535.000 Dollar oder zwei Cents je Aktie im Vorjahrszeitraum. Analysten erwarteten ebenfalls das Erreichen des Break-Even.

Die Umsätze des vierten Quartals fielen leicht von 2,99 auf 2,98 Millionen Dollar. Im Dezember hatte SciClone vor schwächeren Q4-Umsätzen gewarnt auf Grund hoher internationaler Investitionskosten.

Im Jahr 2001 erwartet SciClone ein Umsatzwachstum von 30-40 Prozent.



mehr News... News drucken

15.02.01 13:26 -ps-


_© 2000 Aktienresearch

[Albatossa]

Tuesday February 20, 9:20 am Eastern Time
Press Release
SOURCE: SciClone Pharmaceuticals
SciClone`s ZADAXIN(R) is Able to Increase Anti-Tumor Effects, While Markedly Reducing the Toxicity of Chemotherapy, in Treating Melanoma, Colorectal Cancer, and NSCLC
SAN MATEO, Calif., Feb. 20 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) today announced at the Roth Capital Partners 13th Annual Growth Stock Conference that a review published in the peer-reviewed journal International Journal of Immunopharmacology (Volume 22, pp. 1067-1076) discusses that ZADAXIN®, SciClone`s immune system enhancer (ISE), is able to potentiate the action of cytokines (interferon and interleukin-2) and also reduce the hematological toxicity of cytotoxic drug therapy (cyclophosphamide, 5-fluorouracil, dacarbazine, or ifosfamide based regimens).

The results, published by Enrico Garaci, M.D. and his colleagues at the Department of Experimental Medicine at the University of Rome, provide clinicians and researchers with new insight into the effective use of combination chemo-immunotherapy in the treatment of a variety of common and deadly tumor types. One of the key discoveries of their studies is that thymosin alpha 1, ZADAXIN treatment works best when it is provided following chemotherapy but before cytokine treatment. ``This schedule of treatment seems the most efficient in that it allows each agent to exert its specific function through a metabolic pathway on which the successive agent may properly intervene,`` stated Dr. Garaci.

These studies have also demonstrated the mechanism of action of ZADAXIN and its role as an immune system enhancer (ISE). Triple therapy with ZADAXIN induced the greatest immune stimulation, restoring splenocytes expressing CD3, CD4 and CD8 and also significantly increasing lymphocytes expressing IL-2 receptors (the Th1 subset of CD4 cells). Triple therapy also significantly increased NK (natural killer) and CTL (cytotoxic lymphocyte) cell counts, suggesting that the anti-tumor action was primarily mediated by the host immune response. Another important mechanism of immune stimulation was via the induction of class I MHC molecules on tumor cells, which leads to the recognition and potential cytotoxic destruction by CD8 cells.

In a non-small cell lung cancer (NSCLC) study, combination therapy with ifosfamide, ZADAXIN, and low dose IFN induced 33% major responses and 33% minor responses (in 58% stage IV and 33% stage IIIb patients), whereas patients treated with ifosfamide alone showed a response rate of only 10%. Toxicity was also drastically reduced in patients treated with the triple combination therapy.

ZADAXIN is currently in phase 2 cancer trials worldwide including a malignant melanoma (skin cancer) trial in Australia and a hepatocellular carcinoma (liver cancer) program in the United States. ``This report represents another step forward in the understanding of ZADAXIN`s effects in cancer patients,`` said Alfred R. Rudolph, MD, SciClone`s Chief Operating Officer.

ZADAXIN has been approved for sale in 21 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. ZADAXIN is currently in a phase 3 program in the U.S. in combination with Pegasys® (pegylated interferon alfa-2a) for the treatment of hepatitis C, and in a phase 2 program in combination with lamivudine for the treatment of hepatitis B. In Europe, a pivotal phase 3 ZADAXIN hepatitis C program will complement the Company`s U.S. hepatitis C program. A phase 3 ZADAXIN hepatitis B study is ongoing in Japan as well as a phase 2 trial in hepatitis C. ZADAXIN has been administered to over 3,000 subjects in over 70 clinical trials and an estimated 7,000 patients commercially with virtually no serious drug related side effects or toxicities.

SciClone Pharmaceuticals is a global specialty biopharmaceutical company that acquires, develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. The Company is currently targeting cancer, hepatitis B, hepatitis C, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market® under the symbol SCLN.

The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events, including the ongoing and prospective development and commercialization of ZADAXIN as a potential immunotherapy for cancer, and the timing and results of the Company`s U.S. phase 2 ZADAXIN clinical trials in cancer. Due to market factors and the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company`s filings with the Securities and Exchange Commission.

SOURCE: SciClone Pharmaceuticals

[Babyelch]

Heute mal wieder nachgesehen. Tolle Zahlen. Bin ich froh. Endlich mal ein Lichtblick in meinem Depot.

[Stockdreamer]

Sciclone - Ein Fels in der Brandung. Gerade dann, wenn ringsherum der Sturm tobt, hat diese Aktie die Kraft in positiver Hinsicht aufzufallen. Wie wird sich die Performance erst entwickeln, wenn der Gesamtmarkt dreht? Ich glaube, wir werden in den nächsten Jahren noch viel Freude an unserer Biotech-Perle haben. Go, go Sciclone. Auf zu neuen Höhen.

[CaptainChaos]

Tuesday April 17, 2001 02:03 PM
Company Press Release

SOURCE:SciClone Pharmaceuticals, Inc.


SciClone Receives U.S. Patent Allowance for Analogs of ZADAXIN(R)

SAN MATEO, Calif., April 17 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced it has received a Notice of Allowance for a U.S. patent covering newly described analogs of its lead drug ZADAXIN(R). ZADAXIN is an immune system enhancer (ISE) with an amino acid sequence identical to the naturally occurring peptide, thymosin alpha 1, which plays a key role in the body`s immune response to disease, including the differentiation and maturation of stem cells into "helper" and "killer" T-cells, as well as the identification and "tagging" of infected or cancerous cells for immune intervention.

SciClone has built a portfolio of U.S. and international patents that are intended to protect the use of ZADAXIN for key indications including hepatitis C, hepatitis B and numerous cancers. The new patent will give SciClone exclusive "composition of matter" rights to several families of ZADAXIN analogs the Company has determined could have proprietary therapeutic or biologic distinctions from its current "natural synthetic" formulation, such as length of circulation in the blood or alternative delivery techniques.

"As we move into our phase 3 clinical programs for ZADAXIN in the U.S. and Europe, SciClone is expanding its intellectual property position to cover the most promising analogs of this important compound," said Donald R. Sellers, SciClone`s President and Chief Executive Officer. "This patent, along with our existing patent portfolio, adds to the protection of the substantial hepatitis and cancer franchise we are building with ZADAXIN. It also provides us with future line extension opportunities should we decide to pursue a development program based on the possible incremental advantages offered by our proprietary analogs."

ZADAXIN has been administered to over 3,000 subjects in over 70 clinical trials covering a broad range of diseases and to an estimated 7,000 patients commercially with virtually no serious drug related adverse events or toxicities. ZADAXIN is approved for sale in 21 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. ZADAXIN is currently in a phase 3 program in the U.S. in combination with Pegasys(R) (pegylated interferon alfa-2a) for the treatment of hepatitis C, in a phase 2 program in combination with lamivudine for the treatment of hepatitis B and in a phase 2 trial for the treatment of liver cancer. In Europe, a pivotal phase 3 ZADAXIN hepatitis C program will complement the Company`s U.S. hepatitis C program. ZADAXIN is also in clinical trials in Japan and Australia.

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. The Company is currently targeting malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market(R) under the symbol SCLN.

The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events. These statements include those regarding the ongoing and prospective development and commercialization of ZADAXIN for hepatitis and cancer in the U.S., the timing of enrollment and potential success of the Company`s ZADAXIN clinical trials in hepatitis C, liver cancer, malignant melanoma and drug-resistant tuberculosis. The actual outcomes may differ from those expected due to risks including the inability to obtain regulatory approvals, the failure of the Company`s products to show efficacy in clinical trials or the failure of the Company`s partners to carry out commitments to the Company, and possible entry of competition based on the competitive approvals for indication that are not covered by "use" patents, as well as other risks and uncertainties including those reflected in the Company`s filings with the Securities and Exchange Commission, particularly its Annual Report on Form 10-K for the year ended December 31, 2000.


--------------------------------------------------------------------------------
Contact:
Ruth Koh, Investor Relations of SciClone Pharmaceuticals, Inc.,650-358-3437

[CaptainChaos]

Sciclone - News

P.S. Am 26.04.2001 kommn die Q 1/2001 - Zahlen

National Meeting on ZADAXIN(R) Use in Cancer Held in China;
- New Liver Cancer One-Year Follow-Up Data Presented -
SAN MATEO, Calif., April 23 /PRNewswire Interactive News Release/ --
SciClone Pharmaceuticals (Nasdaq: SCLN) announced that approximately
800 cancer researchers and physicians, including China`s top oncologists,
gathered on Saturday, April 21st, at the Shanghai International Convention
Center for the "National ZADAXIN(R) Meeting on Cancer" in the People`s
Republic of China. More than 40 papers and abstracts were submitted
containing data resulting from cancer research and clinical experience using
ZADAXIN, SciClone`s immune system enhancer (ISE).
The meeting covered three broad topics, each the subject of a formal
session: 1) treatments for cancer using ZADAXIN in combination with
chemotherapy, surgery and other interventions; 2) use of ZADAXIN in the
specific treatment of hepatocellular carcinoma (HCC); and 3) use of ZADAXIN in
the prevention of chemotherapeutic adverse effects.
During the featured second session Dr. W.J. Zhang presented new one-year
follow-up data from a study of HCC patients treated with ZADAXIN plus
transarterial chemoembolization (TACE) led by Dr. Z.S. Li of Changhai Hospital
and The Second Military Medical University. In this study, the combination
treatment resulted in statistically significant improvement in survival rates
at 6, 9 and 12 months following treatment of 91%, 88% and 78% respectively,
compared to rates of 77%, 58% and 46% in a matched historical control group
using TACE alone.
"Cancer represents the next level of ZADAXIN development in the U.S. and
Europe with much of the pioneering research being done in our current
markets," said Donald R. Sellers, SciClone`s President and Chief Executive
Officer. "China has an internationally recognized oncology research community
and important early clinical data has emerged from there. Attending the
meeting, I was particularly interested in the third session. Acceptance of
ZADAXIN as a significant part of combination therapies for cancer treatment in
China can be a key driver for continued sales growth in that country and in
markets worldwide."
The Chinese cancer symposium was sponsored by SciClone as part of the
Company`s worldwide cancer clinical program for ZADAXIN, which includes U.S.
phase 2 liver cancer trials, a phase 2 melanoma trial in Australia, and other
clinical investigations in Italy and China.
ZADAXIN has been administered to over 3,000 subjects in over 70 clinical
trials covering a broad range of diseases and to an estimated 7,000 patients
commercially with virtually no serious drug related adverse events or
toxicities. ZADAXIN is approved for sale in 21 countries, principally for the
treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for
patients with weakened immune systems. ZADAXIN is currently in a phase
3 program in the U.S. in combination with Pegasys(R) (pegylated interferon
alfa-2a) for the treatment of hepatitis C, in a phase 2 program in combination
with lamivudine for the treatment of hepatitis B and in a phase 2 trial for
the treatment of liver cancer. In Europe, a phase 3 ZADAXIN program will
complement the Company`s U.S. hepatitis C program. ZADAXIN is also in
clinical trials in Japan and Australia.

[Albatossa]

Hallo Leute,

Sciclone hat uns heute Abend wirklich ein sehr schlechtes Betriebsergebnis präsentiert. Der Verlust gegenüber dem letzten Jahr wurde sogar um 4 Cent, von 3 Cent auf 7 Cent im 1. Quartal gesteigert. Was mir bereits in der Bilanz negativ außerdem auffiel ist die Tatsache das die Aktienzahl erheblich gesteigert wurde und dadurch wurde das gesamte Ergebnis noch zusätzlich verwässert. Rechnet man die Erhöhung der Aktien von 13 % in einem Jahr noch in das Ergebnis auf und beseitigt dadurch die Verwässerung, so wurde sogar ein Verlust von 8 Cent erwirtschaftet. Was auch sehr bedenklich stimmt ist die Tatsache das der Umsatz im 1. Quartal zurück gegangen ist. Von einer Umsatzsteigerung ist weit und breit leider nichts zu sehen! Der Geldreserven sind ebenfalls durch diesen Verlust zurückgegangen und Sciclone hat zwar noch Geld für fast 3 Jahre, aber dann wird es wirklich sehr eng wenn nicht bald wirkliche Gewinne geschrieben werden.
Der Kurs ist mit -19,8% an der Nasdaq nach dieser Nachricht erheblich in die Knie gegangen. Ob dies alles war glaube ich noch nicht und es ist mit weitere Kursverluste zu rechnen!

Gruß Albatossa


Friday May 11, 6:30 am Eastern Time
Press Release
SOURCE: SciClone Pharmaceuticals
SciClone Pharmaceuticals Reports First Quarter Results
SAN MATEO, Calif., May 11 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news), today reported total revenues for the quarter ended March 31, 2001 from sales of ZADAXIN®, the Company`s immune system enhancer, were $3,113,000 compared to $3,499,000 for the same quarter last year. Net loss for the quarter was $2,125,000, or $.07 per share compared to a net loss of $875,000, or $.03 per share for the same quarter of 2000. SciClone`s cash and short-term investments totaled $21,057,000 at March 31, 2001.

The 11 percent decrease in total revenues for the first quarter of 2001 compared to the same quarter last year was primarily due to lower sales to importing agents in the People`s Republic of China who supply the Company`s distributors in China with ZADAXIN and to increased competition from other hepatitis B therapies. Research and development expenses in the first quarter of 2001 were $1,741,000, a 38% increase over this expense for the first quarter in 2000. As the Company continues to focus on expanding its clinical programs, research and development expenses are expected to rise to higher levels in the remaining quarters of 2001 and through 2002. In addition to the U.S. hepatitis C phase 3 clinical program for ZADAXIN, SciClone is conducting a U.S. phase 2 liver cancer clinical program for ZADAXIN and a U.S. cystic fibrosis clinical program for the Company`s proprietary protein repair therapy, CPX.

``SciClone achieved two major clinical milestones in the first quarter. We initiated our phase 3 hepatitis C clinical program in the United States and we started the CPX program with its new liquid formulation a quarter ahead of plan. As the Company pursues U.S. Food and Drug Administration approval for ZADAXIN and a share of the multi-billion dollar market for hepatitis C in the United States, Europe and Japan, ZADAXIN sales in the developing world continue to be strong,`` said Donald Sellers, SciClone`s President and Chief Executive Officer. ``ZADAXIN sales in emerging markets continue to provide incremental value to SciClone and, together with our strengthened financial resources, provide essentially all of the planned required funding for the ZADAXIN U.S. clinical programs.``

In 2000, the Company added a third importing agent located in the Shanghai area to facilitate the distribution of ZADAXIN in central China. No sales were made to this agent in the fourth quarter of 2000 or in the quarter ended March 31, 2001. The Company will recognize the revenue for any future sales to this importing agent at the time such importing agent sells the product to the distributors. This change will better reflect the timing and the volume of market consumption of ZADAXIN moving through this importing agent. We expect that sales in the current quarter ending June 30, 2001 to be lower than they otherwise would be as some or all of the shipments to this importing agent in the second quarter may not be recognized as revenue until subsequent quarters. This change will not affect the growth of the importing agents` in-market sales of ZADAXIN or cash flow from operations in the quarter and will tend to reduce the length of accounts receivables in future quarters. Management expects to focus the Company`s financial resources on supporting clinical trials in the United States.


First Quarter 2001 Highlights
-- Started pivotal U.S. phase 3 hepatitis C program with ZADAXIN in
combination with Pegasys®, pegylated interferon alfa-2a (being
supplied for the clinical trials by F. Hoffman La-Roche, Ltd. at no
cost to SciClone), to target the largest group of hepatitis C patients
in the United States who are non-responders to the current standard
therapy (alpha interferon or alpha interferon plus ribavirin).
-- Initiated U.S. phase 2 liver cancer trial with ZADAXIN plus radio
frequency ablation (RFA) to evaluate whether a ZADAXIN-enhanced immune
response may contribute to the effectiveness of tumor therapy with RFA.
-- Publication in the International Journal of Immunopharmacology
discussed ZADAXIN`s ability to increase anti-tumor effects, while
markedly reducing the toxicity of chemotherapy, in treating melanoma,
colorectal cancer, and non-small cell lung cancer.
-- Received ZADAXIN marketing approval in India for hepatitis B.


ZADAXIN, a synthetic preparation of thymosin alpha 1, a peptide that occurs naturally in humans and is an immune system enhancer (``ISE``) that helps stimulate, maintain and direct the body`s antiviral or anticancer responses, has been administered to over 3,000 subjects in over 70 clinical trials covering a broad range of diseases and to several thousands of patients commercially around the world with virtually no serious drug related adverse events or toxicities. ZADAXIN is approved for sale in 24 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. ZADAXIN is currently in a phase 3 program in the U.S. in combination with Pegasys®, pegylated interferon alfa-2a, for the treatment of hepatitis C, in a phase 2 program in combination with lamivudine for the treatment of hepatitis B and in a phase 2 trial for the treatment of liver cancer. In Europe, a phase 3 ZADAXIN program will be undertaken which would complement the Company`s U.S. clinical program. ZADAXIN is also in clinical trials in Japan and Australia.

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for treating a broad range of the world`s most serious diseases. The Company has focused its current product development and commercialization activities on hepatitis C, cancer, hepatitis B, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market® under the symbol SCLN.

The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events including the Company`s expectations regarding trends in revenues, gross margins and expenses and statements using the words ``expects,`` ``believes,`` ``anticipates`` or similar words. This includes the ongoing and prospective development, clinical trials and commercialization of ZADAXIN immunotherapy for hepatitis C, cancer, and hepatitis B and the commercial success and continued growth in ZADAXIN sales. Actual events could differ materially from those projected herein, due to risks and uncertainties including market factors, competitive product introductions, the nature of product development, the progress or failure of clinical trials and the regulatory approval process. Additional risks and uncertainties, include those reflected in the Company`s filings with the Securities and Exchange Commission, including those reflected in the Company`s filings with the Securities and Exchange Commission, particularly the Company`s Annual Report on Form 10-K for the year ended December 31, 2000.

SCICLONE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited) (Unaudited)
Three Months Three Months
Ended Ended
March 31, March 31,
2001 2000

Product revenue $3,113,000...... $3,499,000

Cost of product 598,000..... 735,000

Gross margin 2,515,000...... 2,764,000

Operating expenses:
Research and development 1,741,000..... 1,259,000
Marketing 2,277,000..... 1,916,000
General and administrative 830,000..... 643,000

Total operating expenses 4,848,000...... 3,818,000

Loss from operations (2,333,000)...... (1,054,000)
Interest and investment income, net 208,000..... 179,000

Net loss $(2,125,000)...... $(875,000)

Basic net loss per share $(0.07)...... $(0.03)

Weighted average shares used
in computing basic net loss
per share amounts 32,242,093... 28,476,234

SCICLONE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS
March 31, December 31,
2001 2000
(Unaudited)

Cash and cash equivalents/
Short-term investments $21,057,000... $22,497,000
Accounts receivable, net 8,796,000 ... 8,621,000
Inventory 1,961,000... 2,020,000
Other assets 3,232,000... 3,029,000
Total assets $35,046,000... $36,167,000

LIABILITIES AND SHAREHOLDERS` EQUITY

Total liabilities $8,617,000... $8,090,000
Total shareholders` equity 26,429,000... 28,077,000
Total liabilities and shareholders`
equity $35,046,000... $36,167,000

[CaptainChaos]

Es geht wieder aufwärts!!


Tuesday May 22, 2001 07:20 AM
Company Press Release

SOURCE:SciClone Pharmaceuticals


SciClone``s CPX Receives Orphan Drug Status in Europe for Cystic Fibrosis

SAN MATEO, Calif., May 22 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that CPX, the Company`s protein-repair therapy for the treatment of cystic fibrosis (CF), has been granted Orphan Drug Status throughout the European Union (EU). CPX currently is in phase 2 clinical trials in the U.S., where it already has been granted Orphan Drug Status by the U.S. Food and Drug Administration.

"Orphan Drug Status for CPX in the EU as well as the in the U.S., significantly adds to our proprietary position in the world`s major cystic fibrosis markets," said Donald R. Sellers, SciClone`s President and Chief Executive Officer. "This significantly complements our cystic fibrosis program intellectual property position around the world, which already includes patents on CPX and DAX."

Orphan Drug policy in the EU, which was recently legislated, grants ten years of marketing exclusivity upon approval (compared to seven years in the U.S.), assistance in protocol design for clinical trials and a reduction in marketing application fees. In the U.S., there also are certain tax benefits for an Orphan Drug.

Cystic fibrosis is the most common fatal genetic disease among Caucasians. With around 70,000 cases worldwide, it affects approximately 30,000 children and young adults in the U.S. and approximately 30,000 in Europe. There is no cure for the underlying abnormal protein defects (caused by a mutated gene), and the median survival age for CF patients is 31 years. Current treatments address only the symptoms of the disease, primarily the bacterial lung infections that are the most common cause of death in CF patients.

Cystic fibrosis is caused by a defect in the Cystic Fibrosis transmembrane regulator (CFTR) protein. Normally, the CFTR protein transports chloride ions across the membrane of epithelial cells lining several organs in the body such as the lungs and the pancreas. The most debilitating consequence of the defective CFTR protein occurs in the lungs of cystic fibrosis patients where it causes the production of abnormally thick, sticky mucus that clogs the airways and leads to fatal lung infections.

In preclinical studies sponsored by the National Institutes of Health, CPX repaired the two basic CFTR protein-associated defects that cause cystic fibrosis in most patients: (1) it improved the impaired chloride ion transport and (2) it enabled the defective CFTR to reach the epithelial cell membrane (a process called "trafficking"). SciClone believes that its new improved formulation of CPX has the potential to prevent the serious complications of cystic fibrosis, including the production of abnormal mucus.

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for the treatment of a broad range of the world`s most serious diseases. In addition to cystic fibrosis, the Company is currently targeting hepatitis C, liver cancer, malignant melanoma, hepatitis B, HIV and drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market(R) under the symbol SCLN.

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X06921482


--------------------------------------------------------------------------------
Contact:
Ruth Koh, Investor Relations of SciClone Pharmaceuticals,650-358-3437

[erkilein]

damit wird scln zum potentiellen übernahmekandidaten

[CaptainChaos]

@ erkilein,

wer es sich leisten kann. Ich gebe gern eine SCLN für eine Vertex. - lol -

[quickly]

New Published Data Shows Key Role of ZADAXIN(R) in Successful Treatment Of Chronic Hepatitis C
SAN MATEO, Calif., May 23 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) announced that a new study published in the current issue of the peer-reviewed Journal of Viral Hepatitis adds further support to the critical biological role ZADAXIN® contributes to alpha interferon combination therapy used to treat chronic hepatitis C. The study results demonstrate that ZADAXIN increases the production of specific cytokines that fight viral infection while at the same time decreasing the production of other cytokines that make hepatitis C viral infection more impervious to immune response. The study was performed and authored by a group of Italian researchers led by Dr. Pietro Andreone of the University of Bologna.

The study was designed to compare the effects of ZADAXIN and alpha interferon, both separately and together, on cytokine (cell messenger) production in peripheral blood mononuclear cells taken from untreated chronic hepatitis C patients. T-lymphocytes in the body are classified as either Th1 or Th2 depending on the cytokines they produce. Th1 cells primarily produce interleukin-2 (IL-2) and gamma interferon, the cytokines involved in the immune-mediated eradication of the hepatitis C virus. Th2 cells primarily produce interleukin-4 (IL-4) and interleukin-10 (IL-10), which have been associated with the persistence of chronic hepatitis C infection. It has been suggested that when a swing toward Th2 cytokine production occurs it assists the hepatitis C virus to evade clearance by the body`s immune system and thus become chronic.

Results ZADAXIN Produces Increase in Th1 and Correspondent Decrease in Th2

Incubation of cells with ZADAXIN alone resulted in a significant increase in Th1 cytokine production. In addition, ZADAXIN induced a decrease in the Th2 cytokines IL-4 and IL-10. By contrast, incubation with alpha interferon alone resulted in a smaller increase in Th1 cytokines (compared to ZADAXIN) and also an undesirable increase in Th2 cytokine production. Most importantly, the combination of ZADAXIN and alpha interferon resulted in an even greater Th1 increase than either drug alone, and reversed the interferon-based increase in Th2 production.

ZADAXIN treatment also resulted in an increase in 2`5`-oligoadenylate synthetase, a protein with direct antiviral activity.

Conclusion - Combination Therapy Required For Sustained Response

Other recent studies have shown that the clearance of the hepatitis C virus from the body following alpha interferon treatment is a two-phase process: first, the use of alpha interferon produces an initial dose-dependent decline of the viral load based on the prevention of viral replication or release; a second slower phase begins to occur while the viral replication is suppressed and this second phase relates to the clearance or elimination of hepatitis C virally-infected liver cells by the immune system. Although the first phase is seen in the majority of alpha interferon-treated patients, the second, and perhaps more important phase, is seen only in those patients that achieve a sustained response to therapy. A sustained response following hepatitis C therapy means that there is no detectable hepatitis C virus six months after the end of therapy, the time necessary to determine if the virus will return. The overall sustained response rate for alpha interferon monotherapy is around 10%.

An effective hepatitis C virus-specific immune response appears to be necessary for sustained clearance of the hepatitis C virus. The authors conclude that: ``combination treatment of hepatitis C with alpha interferon and ZADAXIN could be ideal, as it stimulates Th1 cell subsets without a concomitant stimulation of Th2. The association of ZADAXIN plus interferon is of interest also because it is very well tolerated and not associated with any significant side effects.``

Company Statement

``This study is extremely encouraging and validating for our recent U.S. phase 3 HCV trials combining ZADAXIN with alpha interferon,`` said Alfred R. Rudolph, MD, SciClone`s Chief Operating Officer. ``Ribavirin has been combined with interferon as the current standard of therapy, and appeared to produce some reversal of increased Th2 production in culture, but it also has added toxicity to the side effect profile and it does not produce the same multi-faceted immune response to infected cells as ZADAXIN. Moreover, long-term response with the ribavirin plus interferon combination is about 28% in the most prevalent and difficult-to-treat variant of the hepatitis C virus (genotype 1). Our ZADAXIN phase 3 study targets the approximately 72% of this patient population that are non-responders to the current standard of care. There is no approved therapy for this group and any significant benefit can be enabling for the medical community.``

Background

The Centers for Disease Control estimate that up to 4 million people in the U.S. are infected with HCV. In its chronic progression, hepatitis C frequently leads to cirrhosis and liver cancer, both potentially fatal conditions. Hepatitis C has now emerged as the leading indication for liver transplantation. No optimal treatment yet exists for chronic hepatitis C. Alpha interferon historically has been the treatment of choice, and increasingly is combined with other therapeutic agents, particularly ribavirin. However, studies of the combination alpha interferon plus ribavirin show a negative response in up to 72% of patients infected with the highly prevalent and difficult-to-treat genotype 1 hepatitis C virus, i.e. they do not have a sustained response. Typically, genotype 1 infection is seen in 75% of the hepatitis C patients in the U.S. Meta-analyses of studies examining the re-treatment of non-responders (those patients that still have hepatitis C virus RNA after 12 months of alpha interferon plus ribavirin therapy) show that less than 8% of this patient group have sustained response after an additional course of therapy with alpha interferon or alpha interferon plus ribavirin. By contrast, in a pooled analysis of previous studies with non-responders, the combination of ZADAXIN plus standard alpha interferon demonstrated a 22% sustained response. Clinical data demonstrate that the combination of ZADAXIN plus interferon could represent a significant therapeutic advance in the global fight against hepatitis C.

ZADAXIN, a synthetic preparation of thymosin alpha 1, a peptide that occurs naturally in humans and is an immune system enhancer (``ISE``) that helps stimulate, maintain and direct the body`s antiviral or anticancer responses, has been administered to over 3,000 subjects in over 70 clinical trials covering a broad range of diseases and to many thousands of patients commercially around the world with virtually no serious drug related adverse events or toxicities. ZADAXIN is approved for sale in 24 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. ZADAXIN is currently in a phase 3 program in the U.S. in combination with Pegasys®, pegylated interferon alfa-2a, for the treatment of hepatitis C, in a phase 2 program in combination with lamivudine for the treatment of hepatitis B and in two phase 2 trials for the treatment of liver cancer. In Europe, a phase 3 ZADAXIN program will be undertaken which would complement the Company`s U.S. clinical program. ZADAXIN is also in clinical trials in Japan and Australia.

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for treating a broad range of the world`s most serious diseases. The Company has focused its current product development and commercialization activities on hepatitis C, cancer, hepatitis B, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800/724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market® under the symbol SCLN.

The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events, prospective development, efficacy and commercialization of ZADAXIN immunotherapy for cancer, hepatitis B and hepatitis C. Due to market factors and the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties that may cause actual results to differ from those stated in this release. These risks and uncertainties include the timing of enrollment and potential success of the Company`s ZADAXIN clinical trials in hepatitis C, liver cancer and malignant melanoma, the speed with which patients are enrolled in the trials and programs, unexpected adverse results to patients during the trials and programs, and other unexpected delays or other events that could prolong the studies or result in unanticipated expense. Additional risks and uncertainties also include those reflected in the Company`s filings with the Securities and Exchange Commission, particularly the Company`s Annual Report on Form 10-K for the year ended December 31, 2000.

[quickly]

Monday July 23, 9:20 am Eastern Time
Press Release
SOURCE: SciClone Pharmaceuticals
SciClone`s ZADAXIN(R) Approved as Cancer Treatment in the Philippines
SAN MATEO, Calif., July 23 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) today announced that ZADAXIN®, the Company`s lead immune system enhancer (ISE) drug, has been approved in The Philippines as an adjuvant to chemotherapy for the treatment of various cancers. ZADAXIN previously was approved in The Philippines for the treatment of both hepatitis C and hepatitis B.

This marks the first time ZADAXIN has been approved specifically for cancer treatment, although in some countries ZADAXIN has been approved for use as an immune system enhancer (ISE) drug without limitation to specific indications. The cancer approval was based on previously reported clinical studies conducted by investigators both in the U.S. and in Italy.

``Clearly, our U.S. hepatitis C phase 3 program is currently the lead corporate imperative, but it is gratifying to receive the first specific regulatory recognition of the ongoing clinical and scientific work that is focused on using ZADAXIN to treat certain cancers,`` said Donald R. Sellers, SciClone`s President and Chief Executive Officer. ``The development of ZADAXIN`s cancer therapy related clinical experience data and safety base is a growing effort.``

Sellers also noted that ZADAXIN currently is being used in two company-sponsored phase 2 U.S. trials for liver cancer, one in combination with transarterial chemoembolization (TACE) and one using radio frequency ablation (RFA), the most widely used procedures for liver tumors that are no longer amenable to surgical resection or liver transplantation. A trial also is underway in Australia using ZADAXIN in a pure immunotherapy combination regimen for the treatment of advanced malignant melanoma.

ZADAXIN is a synthetic preparation of thymosin alpha 1, a peptide that occurs naturally in humans and is an immune system enhancer (``ISE``) that helps stimulate, maintain and direct the body`s antiviral or anticancer responses. It has been administered to over 3,000 subjects in over 70 clinical trials covering a broad range of diseases and to many thousands of patients commercially around the world with virtually no serious drug related adverse events or toxicities. ZADAXIN is approved for sale in 24 countries principally for the treatment of hepatitis B and hepatitis C, and also in certain countries as a vaccine adjuvant for patients with weakened immune systems and as an adjuvant to chemotherapy for the treatment of various cancers. ZADAXIN currently is in a phase 3 program in the U.S. in combination with Pegasys®, pegylated interferon alfa-2a, for the treatment of hepatitis C; a phase 2 program in combination with lamivudine for the treatment of hepatitis B; and in two phase 2 trials for the treatment of liver cancer. A phase 3 ZADAXIN program for European marketing registration currently is being planned for one or more indications that complement the Company`s U.S. clinical program. ZADAXIN is also in clinical trials in Japan and Australia.

SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for treating a broad range of the world`s most serious diseases. The Company has focused its current product development and commercialization activities on hepatitis C, cancer, hepatitis B, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market® under the symbol SCLN.

The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events, including the commencement of clinical trials in Europe and the prospective development, efficacy and commercialization of ZADAXIN immunotherapy for cancer. Due to market factors and the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties that may cause actual results to differ from those stated in this release. These risks and uncertainties include uncertainties as to the timing of enrollment and potential success of the Company`s ZADAXIN clinical trials in hepatitis C, hepatocellular carcinoma and melanoma, the speed with which patients are enrolled in the trials and programs, unexpected adverse results to patients during the trials and programs, and other unexpected delays or other events that could prolong the studies or result in unanticipated expense. Additional risks and uncertainties also include those reflected in the Company`s filings with the Securities and Exchange Commission, particularly the Company`s Annual Report on Form 10-K for the year ended December 31, 2000.